Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Manfred Kneilling is active.

Publication


Featured researches published by Manfred Kneilling.


Nature Medicine | 2008

Simultaneous PET-MRI: a new approach for functional and morphological imaging

Martin S. Judenhofer; Danny F. Newport; Ciprian Catana; Stefan Siegel; Markus Becker; Axel Thielscher; Manfred Kneilling; Matthias P. Lichy; Martin Eichner; Karin Klingel; Gerald Reischl; Stefan Widmaier; Martin Röcken; Robert E. Nutt; Hans Jürgen Machulla; Kamil Uludag; Simon R. Cherry; Claus D. Claussen; Bernd J. Pichler

Noninvasive imaging at the molecular level is an emerging field in biomedical research. This paper introduces a new technology synergizing two leading imaging methodologies: positron emission tomography (PET) and magnetic resonance imaging (MRI). Although the value of PET lies in its high-sensitivity tracking of biomarkers in vivo, it lacks resolving morphology. MRI has lower sensitivity, but produces high soft-tissue contrast and provides spectroscopic information and functional MRI (fMRI). We have developed a three-dimensional animal PET scanner that is built into a 7-T MRI. Our evaluations show that both modalities preserve their functionality, even when operated isochronously. With this combined imaging system, we simultaneously acquired functional and morphological PET-MRI data from living mice. PET-MRI provides a powerful tool for studying biology and pathology in preclinical research and has great potential for clinical applications. Combining fMRI and spectroscopy with PET paves the way for a new perspective in molecular imaging.


Nature | 2013

T-helper-1-cell cytokines drive cancer into senescence

Heidi Braumüller; Thomas Wieder; Ellen Brenner; Sonja Aßmann; Matthias Hahn; Mohammed Alkhaled; Karin Schilbach; Frank Essmann; Manfred Kneilling; Christoph M. Griessinger; Felicia Ranta; Susanne Ullrich; Ralph Mocikat; Kilian Braungart; Tarun Mehra; Birgit Fehrenbacher; Julia Berdel; Heike Niessner; Friedegund Meier; Maries van den Broek; Hans-Ulrich Häring; Rupert Handgretinger; Leticia Quintanilla-Martinez; Falko Fend; Marina Pesic; Jürgen Bauer; Lars Zender; Martin Schaller; Klaus Schulze-Osthoff; Martin Röcken

Cancer control by adaptive immunity involves a number of defined death and clearance mechanisms. However, efficient inhibition of exponential cancer growth by T cells and interferon-γ (IFN-γ) requires additional undefined mechanisms that arrest cancer cell proliferation. Here we show that the combined action of the T-helper-1-cell cytokines IFN-γ and tumour necrosis factor (TNF) directly induces permanent growth arrest in cancers. To safely separate senescence induced by tumour immunity from oncogene-induced senescence, we used a mouse model in which the Simian virus 40 large T antigen (Tag) expressed under the control of the rat insulin promoter creates tumours by attenuating p53- and Rb-mediated cell cycle control. When combined, IFN-γ and TNF drive Tag-expressing cancers into senescence by inducing permanent growth arrest in G1/G0, activation of p16INK4a (also known as CDKN2A), and downstream Rb hypophosphorylation at serine 795. This cytokine-induced senescence strictly requires STAT1 and TNFR1 (also known as TNFRSF1A) signalling in addition to p16INK4a. In vivo, Tag-specific T-helper 1 cells permanently arrest Tag-expressing cancers by inducing IFN-γ- and TNFR1-dependent senescence. Conversely, Tnfr1−/− Tag-expressing cancers resist cytokine-induced senescence and grow aggressively, even in TNFR1-expressing hosts. Finally, as IFN-γ and TNF induce senescence in numerous murine and human cancers, this may be a general mechanism for arresting cancer progression.


Cancer Cell | 2008

TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis

Nele Müller-Hermelink; Heidi Braumüller; Bernd J. Pichler; Thomas Wieder; Reinhard Mailhammer; Katrin Schaak; Kamran Ghoreschi; Amir S. Yazdi; Christian A. Sander; Ralph Mocikat; Markus Schwaiger; Irmgard Förster; Ralph Huss; Wolfgang A. Weber; Manfred Kneilling; Martin Röcken

Immune responses may arrest tumor growth by inducing tumor dormancy. The mechanisms leading to either tumor dormancy or promotion of multistage carcinogenesis by adaptive immunity are poorly characterized. Analyzing T antigen (Tag)-induced multistage carcinogenesis in pancreatic islets, we show that Tag-specific CD4+ T cells home selectively into the tumor microenvironment around the islets, where they either arrest or promote transition of dysplastic islets into islet carcinomas. Through combined TNFR1 signaling and IFN-gamma signaling, Tag-specific CD4+ T cells induce antiangiogenic chemokines and prevent alpha(v)beta(3) integrin expression, tumor angiogenesis, tumor cell proliferation, and multistage carcinogenesis, without destroying Tag-expressing islet cells. In the absence of either TNFR1 signaling or IFN-gamma signaling, the same T cells paradoxically promote angiogenesis and multistage carcinogenesis. Thus, tumor-specific T cells can directly survey multistage carcinogenesis through cytokine signaling.


Nature Immunology | 2014

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3

Dominic De Nardo; Larisa I. Labzin; Hajime Kono; Reiko Seki; Susanne Schmidt; Marc Beyer; Dakang Xu; Sebastian Zimmer; Catharina Lahrmann; Frank A. Schildberg; Johanna Vogelhuber; Michael Kraut; Thomas Ulas; Anja Kerksiek; Wolfgang Krebs; Niklas Bode; Alena Grebe; Michael L. Fitzgerald; Nicholas J. Hernandez; Bryan R. G. Williams; Percy A. Knolle; Manfred Kneilling; Martin Röcken; Dieter Lütjohann; Samuel D. Wright; Joachim L. Schultze; Eicke Latz

High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional regulator ATF3, as an HDL-inducible target gene in macrophages that downregulates the expression of Toll-like receptor (TLR)-induced proinflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of new HDL-based therapies.


Nature Medicine | 2012

ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression

Wolfram Hoetzenecker; Bernd Echtenacher; Emmanuella Guenova; Konrad Hoetzenecker; Florian Woelbing; Jürgen Brück; Anna Teske; Nadejda Valtcheva; Kerstin Fuchs; Manfred Kneilling; Ji-Hyeon Park; Kyu-Han Kim; Kyu-Won Kim; Petra Hoffmann; Claus G. Krenn; Tsonwin Hai; Kamran Ghoreschi; Tilo Biedermann; Martin Röcken

Sepsis, sepsis-induced hyperinflammation and subsequent sepsis-associated immunosuppression (SAIS) are important causes of death. Here we show in humans that the loss of the major reactive oxygen species (ROS) scavenger, glutathione (GSH), during SAIS directly correlates with an increase in the expression of activating transcription factor 3 (ATF3). In endotoxin-stimulated monocytes, ROS stress strongly superinduced NF-E2–related factor 2 (NRF2)–dependent ATF3. In vivo, this ROS-mediated superinduction of ATF3 protected against endotoxic shock by inhibiting innate cytokines, as Atf3−/− mice remained susceptible to endotoxic shock even under conditions of ROS stress. Although it protected against endotoxic shock, this ROS-mediated superinduction of ATF3 caused high susceptibility to bacterial and fungal infections through the suppression of interleukin 6 (IL-6). As a result, Atf3−/− mice were protected against bacterial and fungal infections, even under conditions of ROS stress, whereas Atf3−/−Il6−/− mice were highly susceptible to these infections. Moreover, in a model of SAIS, secondary infections caused considerably less mortality in Atf3−/− mice than in wild-type mice, indicating that ROS-induced ATF3 crucially determines susceptibility to secondary infections during SAIS.


Blood | 2009

Direct Crosstalk between Mast Cell-TNF and TNFR1-expressing Endothelia Mediates Local Tissue Inflammation

Manfred Kneilling; Reinhard Mailhammer; Lothar Hültner; Tanja Schönberger; Kerstin Fuchs; Martin Schaller; Daniel Bukala; Steffen Massberg; Christian A. Sander; Heidi Braumüller; Martin Eichner; Konrad Maier; Rupert Hallmann; Bernd J. Pichler; Roland Haubner; Meinrad Gawaz; Klaus Pfeffer; Tilo Biedermann; Martin Röcken

Signaling through tumor necrosis factor receptor 1 (TNFR1) controls bacterial infections and the induction of inflammatory Th1 cell-mediated autoimmune diseases. By dissecting Th1 cell-mediated delayed-type hypersensitivity responses (DTHRs) into single steps, we localized a central defect to the missing TNFR1 expression by endothelial cells (ECs). Adoptive transfer and mast cell knockin experiments into Kit(W)/Kit(W-v), TNF(-/-), and TNFR1(-/-) mice showed that the signaling defect exclusively affects mast cell-EC interactions but not T cells or antigen-presenting cells. As a consequence, TNFR1(-/-) mice had strongly reduced mRNA and protein expression of P-selectin, E-selectin, ICAM-1, and VCAM-1 during DTHR elicitation. In consequence, intravital fluorescence microscopy revealed up to 80% reduction of leukocyte rolling and firm adhesion in TNFR1(-/-) mice. As substitution of TNF(-/-) mice with TNF-producing mast cells fully restored DTHR in these mice, signaling of mast cell-derived TNF through TNFR1-expressing ECs is essential for the recruitment of leukocytes into sites of inflammation.


Experimental Dermatology | 2009

Mast cells: novel clinical perspectives from recent insights

Manfred Kneilling; Martin Röcken

Abstract:  Mast cells are still generally viewed as mediators of type I allergic or pseudoallergic reactions. Research over the past 10 years revealed that our view was too small and that mast cells are of key importance in innate immunity and also types II, III and IV adaptive immune reactions. Understanding their role in modulating and amplifying of inflammatory responses provides important insights into the pathogenesis of skin diseases such as psoriasis, atopic dermatitis, bullous pemphigoid or the control of infections. This helps us to understand the course of these diseases, their trigger mechanisms, and, the new role of agents, which can modulate the function of mast cells. These insights will help to develop new therapeutic approaches.


Cell Cycle | 2008

T cell-mediated help against tumors

Thomas Wieder; Heidi Braumüller; Manfred Kneilling; Bernd J. Pichler; Martin Röcken

Adoptive transfer of tumor antigen-specific T helper (Th) cells is a surprisingly potent anti-tumor therapy. Even in RIP1-Tag2 mice with a rapidly growing, aggressive endogenous beta cell tumor Th can significantly extend life time and are more efficient than any other therapy studied. The therapeutic effect of Th cells seems to be independent of tumor cell destruction. It critically relies on three principles: (i) inhibition of tumor angiogenesis, (ii) inhibition of beta cell proliferation, and (iii) induction of tumor dormancy. As tumor cell destruction by cytotoxic CD8+ T cells (CTL) largely failed in tumor therapy, induction of tumor dormancy by Th cell-mediated immune responses represents a novel therapeutic option that may be combined with other cytotoxic regimens, e. g. radio- and/or chemotherapy, as it is established for bone marrow transplantation. Importantly, Th cell efficacy strictly requires interferon-gamma (IFN-gamma) signaling, and, in the absence of IFN-gamma, Th cells may even worsen tumor diseases. Therefore, using the immune system to control tumor dormancy represents a novel approach, especially as therapy of tumors resistant to conventional therapies. Yet, it is important to underline that Th cell-based antitumor effects critically depend on a functional cytokine network, especially appropriate IFN-gamma signaling.


Journal of Immunology | 2002

Subunits of IgM Reconstitute Defective Contact Sensitivity in B-1 Cell-Deficient xid Mice: κ Light Chains Recruit T Cells Independent of Complement

Vipin Paliwal; Ryohei F. Tsuji; Marian Szczepanik; Ivana Kawikova; Regis A. Campos; Manfred Kneilling; Martin Röcken; Janine Schuurman; Frank A. Redegeld; Frans P. Nijkamp; Philip W. Askenase

The elicitation of contact sensitivity (CS) to local skin challenge with the hapten trinitrophenyl (TNP) chloride requires an early process that is necessary for local recruitment of CS-effector T cells. This is called CS initiation and is due to the B-1 subset of B cells activated at immunization to produce circulating IgM Ab. At challenge, the IgM binds hapten Ag in a complex that locally activates C to generate C5a that aids in T cell recruitment. In this study, we present evidence that CS initiation is indeed mediated by C-activating classic IgM anti-TNP pentamer. We further demonstrate the involvement of IgM subunits derived either from hybridomas or from lymphoid cells of actively immunized mice. Thus, reduced and alkylated anti-TNP IgM also initiates CS, likely due to generated H chain-L chain dimers, as does a mixture of separated H and L chains that still could weakly bind hapten, but could not activate C. Remarkably, anti-TNP κ L chains alone mediated CS initiation that was C-independent, but was dependent on mast cells. Thus, B-1 cell-mediated CS initiation required for T cell recruitment is due to activation of C by specific IgM pentamer, and also subunits of IgM, while κ L chains act via another C-independent but mast cell-dependent pathway.


Blood | 2011

PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability

Yasuko Furumoto; Nicolas Charles; Ana Olivera; Wai Hang Leung; Sandra Dillahunt; Jennifer L. Sargent; Kevin W. Tinsley; Sandra Odom; Eric Scott; Todd M. Wilson; Kamran Ghoreschi; Manfred Kneilling; Mei Chen; David M. Lee; Silvia Bolland; Juan Rivera

Kit regulation of mast cell proliferation and differentiation has been intimately linked to the activation of phosphatidylinositol 3-OH kinase (PI3K). The activating D816V mutation of Kit, seen in the majority of mastocytosis patients, causes a robust activation of PI3K signals. However, whether increased PI3K signaling in mast cells is a key element for their in vivo hyperplasia remains unknown. Here we report that dysregulation of PI3K signaling in mice by deletion of the phosphatase and tensin homolog (Pten) gene (which regulates the levels of the PI3K product, phosphatidylinositol 3,4,5-trisphosphate) caused mast cell hyperplasia and increased numbers in various organs. Selective deletion of Pten in the mast cell compartment revealed that the hyperplasia was intrinsic to the mast cell. Enhanced STAT5 phosphorylation and increased expression of survival factors, such as Bcl-XL, were observed in PTEN-deficient mast cells, and these were further enhanced by stem cell factor stimulation. Mice carrying PTEN-deficient mast cells also showed increased hypersensitivity as well as increased vascular permeability. Thus, Pten deletion in the mast cell compartment results in a mast cell proliferative phenotype in mice, demonstrating that dysregulation of PI3K signals is vital to the observed mast cell hyperplasia.

Collaboration


Dive into the Manfred Kneilling's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge